Aug 1, 2021
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Reactions Weekly
Abstract
Miricorilant reduces olanzapine-associated weight gain in health subjects, according to a study conducted in the UK. The randomised, double-blind phase 1 study examined the difference in mean change in absolute body weight from baseline following 14 days of coadministration of olanzapine 10mg once daily and miricorilant 600mg (6 × 100mg) once daily, compared with olanzapine and placebo.* The effects of miricorilant on olanzapine-associated increases in serum insulin, insulin resistance and triclycerides were also examined. The exploratory proof-of-concept was conducted at a phase 1 research facility that specialises in recruiting healthy volunteers for interventional studies. The analysis of data from 66 subjects showed that mean increases in body weight on both days 8 and 15 were significantly lower among those subjects receiving olanzapine plus miricorilant (n = 33), compared with the placebo group (2.59kg and 3.91kg, respectively, vs 3.49kg and 4.98kg, respectively). Furthermore, coadministration of miricorilant with olanzapine was associated with significantly smaller mean increases in insulin as well as homeostatic model assessment of insulin resistance on both days 8 and 15. Coadministration of miricorilant with olanzapine was also associated with smaller serum triglyceride increases on both days 8 and 15. "These positive results support the development of miricorilant for the treatment of patients with AIWG [antipsychotic-induced weigh gain]," conclude the researchers. The study also showed that miricorilant reduced olanzapine-induced elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels.